VictORION-INCLUSION is a Multicenter, Randomized, Open Label, Study of Inclisiran + Usual Care vs Usual Care Alone in an Inclusive and Underrepresented Population at High Risk for or Diagnosed With ASCVD Within a Pragmatic EHR Framework (V-INCLUSION) - The National Patient-Centered Clinical Research Network

Study Updated 05/13/2024

ClinicalTrials.gov#: NCT06249165
Study Design: Interventional
PCORnet Infrastructure: Collaboration, CDM (+supplemental data), Engagement, Single IRB
Principal Investigator: Neha Pagidipati
Site Name: Duke Clinical Research Institute
PCORnet® Network Partner: Coordinating Center
Funder: Novartis
Funding Date: 2023
Study Duration: 2023 – 2025
Participating Clinical Research Networks: GPC, OneFlorida+, PaTH, REACHnet, STAR
Therapeutic Area: Cardiovascular
Condition: Atherosclerotic Cardiovascular Disease (ASCVD)
Status: Not yet recruiting

Research Question(s):
Can inclisiran be an effective solution to improve low-density lipoprotein-cholesterol management and close care gaps in an inclusive Atherosclerotic Cardiovascular Disease (ASCVD) and ASCVD risk equivalent population?

SUBSCRIBE